ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Published Date: March 2024
|
Report Code: QYRE-Auto-19W6917
Home | Market Reports | Health| Health Conditions| Cancer
China Circulating Tumor Cells CTCs and Cancer Stem Cells CSCs Market Report Forecast 2021 2027
BUY CHAPTERS

Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-19W6917
Report
March 2024
Pages:165
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Janssen
Qiagen NV
Advanced Cell Diagnostics
Apocell Inc
Biofluidica
Clearbridge Biomedics
CytoTrack
Celsee
Fluxion
Gilupi
Cynvenio
On-chip
YZY Bio
BioView
Fluidigm
Ikonisys
AdnaGen AG
IVDiagnostics
Miltenyi Biotec
ScreenCell
Silicon Biosystems

Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) - Market Size

The global market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) was estimated to be worth US$ 14380 million in 2023 and is forecast to a readjusted size of US$ 56720 million by 2030 with a CAGR of 21.4% during the forecast period 2024-2030

Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) - Market

Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) - Market

Circulating tumor cells (CTCs) are tumor cells that detach from the primary tumor and travel in the bloodstream, spreading from the original tumor to other locations, leading to cancer metastasis. These cells exist in peripheral blood of cancer patients and detection of CTCs can help to determine the process of metastasis. In contrast with other blood cells, the number of CTCs is very rare in blood which makes them difficult to detect.
Cancer stem cells (CSCs) are cancer cells that have all the classical properties of normal stem cells. Specifically, they are able to both give rise to more copies of themselves and to give rise to all cell types found in the cancer.
The major players in global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market include Janssen, Qiagen, Advanced Cell Diagnostics, etc. North America and Europe are main markets, they occupy about 65% of the global market. CellSearch is the main type, with a share about 70%. Breast Cancer Diagnosis and Treatment, Colorectal Cancer Diagnosis and Treatment are main applications, which hold a share about 60%.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs), focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) by region & country, by Type, and by Application.
The Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs).
Market Segmentation

Scope of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) - Market Report

Report Metric Details
Report Name Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) - Market
Forecasted market size in 2030 US$ 56720 million
CAGR 21.4%
Forecasted years 2024 - 2030
Segment by Type:
  • CellSearch
  • Others
Segment by Application
  • Breast Cancer Diagnosis and Treatment
  • Prostate Cancer Diagnosis and Treatment
  • Colorectal Cancer Diagnosis and Treatment
  • Lung Cancer Diagnosis and Treatment
  • Other Cancers Diagnosis and Treatment
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Janssen, Qiagen, Advanced Cell Diagnostics, ApoCell, Biofluidica, Clearbridge Biomedics, CytoTrack, Celsee, Fluxion, Gilupi, Cynvenio, On-chip, YZY Bio, BioView, Fluidigm, Ikonisys, AdnaGen, IVDiagnostics, Miltenyi Biotec, ScreenCell, Silicon Biosystems
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 2: Detailed analysis of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 5: Revenue of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 6: Revenue of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) in country level. It provides sigmate data by Type, and by Application for each country/region.
  • Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
  • Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 9: Conclusion.

FAQ for this report

What is the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) - Market size in 2030?

Ans: The Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) - Market size in 2030 will be US$ 56720 million.

What is the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) - Market share by type?

Ans: CellSearch is the main type, with a share about 70%.

Who are the main players in the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) - Market report?

Ans: The main players in the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) - Market are Janssen, Qiagen, Advanced Cell Diagnostics, ApoCell, Biofluidica, Clearbridge Biomedics, CytoTrack, Celsee, Fluxion, Gilupi, Cynvenio, On-chip, YZY Bio, BioView, Fluidigm, Ikonisys, AdnaGen, IVDiagnostics, Miltenyi Biotec, ScreenCell, Silicon Biosystems

What are the Application segmentation covered in the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) - Market report?

Ans: The Applications covered in the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) - Market report are Breast Cancer Diagnosis and Treatment, Prostate Cancer Diagnosis and Treatment, Colorectal Cancer Diagnosis and Treatment, Lung Cancer Diagnosis and Treatment, Other Cancers Diagnosis and Treatment

What are the Type segmentation covered in the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) - Market report?

Ans: The Types covered in the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) - Market report are CellSearch, Others

1 Market Overview
1.1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Introduction
1.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size Forecast
1.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Trends & Drivers
1.3.1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Industry Trends
1.3.2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Drivers & Opportunity
1.3.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Challenges
1.3.4 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Players Revenue Ranking (2023)
2.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Company (2019-2024)
2.3 Key Companies Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Manufacturing Base Distribution and Headquarters
2.4 Key Companies Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Offered
2.5 Key Companies Time to Begin Mass Production of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs)
2.6 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Competitive Analysis
2.6.1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 CellSearch
3.1.2 Others
3.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type
3.2.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, by Type (2019-2030)
3.2.3 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Breast Cancer Diagnosis and Treatment
4.1.2 Prostate Cancer Diagnosis and Treatment
4.1.3 Colorectal Cancer Diagnosis and Treatment
4.1.4 Lung Cancer Diagnosis and Treatment
4.1.5 Other Cancers Diagnosis and Treatment
4.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application
4.2.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, by Application (2019-2030)
4.2.3 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Region
5.1.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Region (2019-2024)
5.1.3 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Region (2025-2030)
5.1.4 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2019-2030
5.2.2 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2019-2030
5.3.2 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2019-2030
5.4.2 Asia Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2019-2030
5.5.2 South America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2019-2030
5.6.2 Middle East & Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value
6.3 United States
6.3.1 United States Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2019-2030
6.3.2 United States Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2019-2030
6.4.2 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2019-2030
6.5.2 China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2023 VS 2030
6.5.3 China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2019-2030
6.6.2 Japan Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2019-2030
6.7.2 South Korea Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2019-2030
6.8.2 Southeast Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2019-2030
6.9.2 India Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2023 VS 2030
6.9.3 India Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Janssen
7.1.1 Janssen Profile
7.1.2 Janssen Main Business
7.1.3 Janssen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.1.4 Janssen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.1.5 Janssen Recent Developments
7.2 Qiagen
7.2.1 Qiagen Profile
7.2.2 Qiagen Main Business
7.2.3 Qiagen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.2.4 Qiagen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.2.5 Qiagen Recent Developments
7.3 Advanced Cell Diagnostics
7.3.1 Advanced Cell Diagnostics Profile
7.3.2 Advanced Cell Diagnostics Main Business
7.3.3 Advanced Cell Diagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.3.4 Advanced Cell Diagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.3.5 ApoCell Recent Developments
7.4 ApoCell
7.4.1 ApoCell Profile
7.4.2 ApoCell Main Business
7.4.3 ApoCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.4.4 ApoCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.4.5 ApoCell Recent Developments
7.5 Biofluidica
7.5.1 Biofluidica Profile
7.5.2 Biofluidica Main Business
7.5.3 Biofluidica Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.5.4 Biofluidica Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.5.5 Biofluidica Recent Developments
7.6 Clearbridge Biomedics
7.6.1 Clearbridge Biomedics Profile
7.6.2 Clearbridge Biomedics Main Business
7.6.3 Clearbridge Biomedics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.6.4 Clearbridge Biomedics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.6.5 Clearbridge Biomedics Recent Developments
7.7 CytoTrack
7.7.1 CytoTrack Profile
7.7.2 CytoTrack Main Business
7.7.3 CytoTrack Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.7.4 CytoTrack Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.7.5 CytoTrack Recent Developments
7.8 Celsee
7.8.1 Celsee Profile
7.8.2 Celsee Main Business
7.8.3 Celsee Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.8.4 Celsee Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.8.5 Celsee Recent Developments
7.9 Fluxion
7.9.1 Fluxion Profile
7.9.2 Fluxion Main Business
7.9.3 Fluxion Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.9.4 Fluxion Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.9.5 Fluxion Recent Developments
7.10 Gilupi
7.10.1 Gilupi Profile
7.10.2 Gilupi Main Business
7.10.3 Gilupi Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.10.4 Gilupi Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.10.5 Gilupi Recent Developments
7.11 Cynvenio
7.11.1 Cynvenio Profile
7.11.2 Cynvenio Main Business
7.11.3 Cynvenio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.11.4 Cynvenio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.11.5 Cynvenio Recent Developments
7.12 On-chip
7.12.1 On-chip Profile
7.12.2 On-chip Main Business
7.12.3 On-chip Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.12.4 On-chip Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.12.5 On-chip Recent Developments
7.13 YZY Bio
7.13.1 YZY Bio Profile
7.13.2 YZY Bio Main Business
7.13.3 YZY Bio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.13.4 YZY Bio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.13.5 YZY Bio Recent Developments
7.14 BioView
7.14.1 BioView Profile
7.14.2 BioView Main Business
7.14.3 BioView Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.14.4 BioView Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.14.5 BioView Recent Developments
7.15 Fluidigm
7.15.1 Fluidigm Profile
7.15.2 Fluidigm Main Business
7.15.3 Fluidigm Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.15.4 Fluidigm Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.15.5 Fluidigm Recent Developments
7.16 Ikonisys
7.16.1 Ikonisys Profile
7.16.2 Ikonisys Main Business
7.16.3 Ikonisys Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.16.4 Ikonisys Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.16.5 Ikonisys Recent Developments
7.17 AdnaGen
7.17.1 AdnaGen Profile
7.17.2 AdnaGen Main Business
7.17.3 AdnaGen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.17.4 AdnaGen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.17.5 AdnaGen Recent Developments
7.18 IVDiagnostics
7.18.1 IVDiagnostics Profile
7.18.2 IVDiagnostics Main Business
7.18.3 IVDiagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.18.4 IVDiagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.18.5 IVDiagnostics Recent Developments
7.19 Miltenyi Biotec
7.19.1 Miltenyi Biotec Profile
7.19.2 Miltenyi Biotec Main Business
7.19.3 Miltenyi Biotec Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.19.4 Miltenyi Biotec Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.19.5 Miltenyi Biotec Recent Developments
7.20 ScreenCell
7.20.1 ScreenCell Profile
7.20.2 ScreenCell Main Business
7.20.3 ScreenCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.20.4 ScreenCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.20.5 ScreenCell Recent Developments
7.21 Silicon Biosystems
7.21.1 Silicon Biosystems Profile
7.21.2 Silicon Biosystems Main Business
7.21.3 Silicon Biosystems Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
7.21.4 Silicon Biosystems Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2019-2024)
7.21.5 Silicon Biosystems Recent Developments
8 Industry Chain Analysis
8.1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Industrial Chain
8.2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Model
8.5.2 Sales Channel
8.5.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
FEATURED COMPANIES
Janssen
Qiagen NV
Advanced Cell Diagnostics
Apocell Inc
Biofluidica
Clearbridge Biomedics
CytoTrack
Celsee
Fluxion
Gilupi
Cynvenio
On-chip
YZY Bio
BioView
Fluidigm
Ikonisys
AdnaGen AG
IVDiagnostics
Miltenyi Biotec
ScreenCell
Silicon Biosystems
List of Tables
    Table 1. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Trends
    Table 2. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Drivers & Opportunity
    Table 3. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Challenges
    Table 4. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Restraints
    Table 5. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Type
    Table 9. Key Companies Time to Begin Mass Production of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs)
    Table 10. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Region (2019-2024) & (%)
    Table 27. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, (2025-2030) & (US$ Million)
    Table 31. Janssen Basic Information List
    Table 32. Janssen Description and Business Overview
    Table 33. Janssen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 34. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Janssen (2019-2024)
    Table 35. Janssen Recent Developments
    Table 36. Qiagen Basic Information List
    Table 37. Qiagen Description and Business Overview
    Table 38. Qiagen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 39. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Qiagen (2019-2024)
    Table 40. Qiagen Recent Developments
    Table 41. Advanced Cell Diagnostics Basic Information List
    Table 42. Advanced Cell Diagnostics Description and Business Overview
    Table 43. Advanced Cell Diagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 44. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Advanced Cell Diagnostics (2019-2024)
    Table 45. Advanced Cell Diagnostics Recent Developments
    Table 46. ApoCell Basic Information List
    Table 47. ApoCell Description and Business Overview
    Table 48. ApoCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 49. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of ApoCell (2019-2024)
    Table 50. ApoCell Recent Developments
    Table 51. Biofluidica Basic Information List
    Table 52. Biofluidica Description and Business Overview
    Table 53. Biofluidica Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 54. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Biofluidica (2019-2024)
    Table 55. Biofluidica Recent Developments
    Table 56. Clearbridge Biomedics Basic Information List
    Table 57. Clearbridge Biomedics Description and Business Overview
    Table 58. Clearbridge Biomedics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 59. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Clearbridge Biomedics (2019-2024)
    Table 60. Clearbridge Biomedics Recent Developments
    Table 61. CytoTrack Basic Information List
    Table 62. CytoTrack Description and Business Overview
    Table 63. CytoTrack Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 64. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of CytoTrack (2019-2024)
    Table 65. CytoTrack Recent Developments
    Table 66. Celsee Basic Information List
    Table 67. Celsee Description and Business Overview
    Table 68. Celsee Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 69. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Celsee (2019-2024)
    Table 70. Celsee Recent Developments
    Table 71. Fluxion Basic Information List
    Table 72. Fluxion Description and Business Overview
    Table 73. Fluxion Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 74. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Fluxion (2019-2024)
    Table 75. Fluxion Recent Developments
    Table 76. Gilupi Basic Information List
    Table 77. Gilupi Description and Business Overview
    Table 78. Gilupi Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 79. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Gilupi (2019-2024)
    Table 80. Gilupi Recent Developments
    Table 81. Cynvenio Basic Information List
    Table 82. Cynvenio Description and Business Overview
    Table 83. Cynvenio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 84. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Cynvenio (2019-2024)
    Table 85. Cynvenio Recent Developments
    Table 86. On-chip Basic Information List
    Table 87. On-chip Description and Business Overview
    Table 88. On-chip Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 89. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of On-chip (2019-2024)
    Table 90. On-chip Recent Developments
    Table 91. YZY Bio Basic Information List
    Table 92. YZY Bio Description and Business Overview
    Table 93. YZY Bio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 94. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of YZY Bio (2019-2024)
    Table 95. YZY Bio Recent Developments
    Table 96. BioView Basic Information List
    Table 97. BioView Description and Business Overview
    Table 98. BioView Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 99. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of BioView (2019-2024)
    Table 100. BioView Recent Developments
    Table 101. Fluidigm Basic Information List
    Table 102. Fluidigm Description and Business Overview
    Table 103. Fluidigm Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 104. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Fluidigm (2019-2024)
    Table 105. Fluidigm Recent Developments
    Table 106. Ikonisys Basic Information List
    Table 107. Ikonisys Description and Business Overview
    Table 108. Ikonisys Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 109. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Ikonisys (2019-2024)
    Table 110. Ikonisys Recent Developments
    Table 111. AdnaGen Basic Information List
    Table 112. AdnaGen Description and Business Overview
    Table 113. AdnaGen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 114. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of AdnaGen (2019-2024)
    Table 115. AdnaGen Recent Developments
    Table 116. IVDiagnostics Basic Information List
    Table 117. IVDiagnostics Description and Business Overview
    Table 118. IVDiagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 119. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of IVDiagnostics (2019-2024)
    Table 120. IVDiagnostics Recent Developments
    Table 121. Miltenyi Biotec Basic Information List
    Table 122. Miltenyi Biotec Description and Business Overview
    Table 123. Miltenyi Biotec Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 124. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Miltenyi Biotec (2019-2024)
    Table 125. Miltenyi Biotec Recent Developments
    Table 126. ScreenCell Basic Information List
    Table 127. ScreenCell Description and Business Overview
    Table 128. ScreenCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 129. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of ScreenCell (2019-2024)
    Table 130. ScreenCell Recent Developments
    Table 131. Silicon Biosystems Basic Information List
    Table 132. Silicon Biosystems Description and Business Overview
    Table 133. Silicon Biosystems Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
    Table 134. Revenue (US$ Million) in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business of Silicon Biosystems (2019-2024)
    Table 135. Silicon Biosystems Recent Developments
    Table 136. Key Raw Materials Lists
    Table 137. Raw Materials Key Suppliers Lists
    Table 138. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Downstream Customers
    Table 139. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Distributors List
    Table 140. Research Programs/Design for This Report
    Table 141. Key Data Information from Secondary Sources
    Table 142. Key Data Information from Primary Sources
    Table 143. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Picture
    Figure 2. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value (2019-2030) & (US$ Million)
    Figure 4. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Report Years Considered
    Figure 5. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue in 2023
    Figure 7. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. CellSearch Picture
    Figure 9. Others Picture
    Figure 10. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 11. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value Market Share by Type, 2023 & 2030
    Figure 12. Product Picture of Breast Cancer Diagnosis and Treatment
    Figure 13. Product Picture of Prostate Cancer Diagnosis and Treatment
    Figure 14. Product Picture of Colorectal Cancer Diagnosis and Treatment
    Figure 15. Product Picture of Lung Cancer Diagnosis and Treatment
    Figure 16. Product Picture of Other Cancers Diagnosis and Treatment
    Figure 17. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 18. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value Market Share by Application, 2023 & 2030
    Figure 19. North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value (2019-2030) & (US$ Million)
    Figure 20. North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Country (%), 2023 VS 2030
    Figure 21. Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value (2019-2030) & (US$ Million)
    Figure 22. Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Country (%), 2023 VS 2030
    Figure 23. Asia Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value (2019-2030) & (US$ Million)
    Figure 24. Asia Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Country (%), 2023 VS 2030
    Figure 25. South America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value (2019-2030) & (US$ Million)
    Figure 26. South America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Country (%), 2023 VS 2030
    Figure 27. Middle East & Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value (2019-2030) & (US$ Million)
    Figure 28. Middle East & Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Country (%), 2023 VS 2030
    Figure 29. Key Countries/Regions Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value (%), (2019-2030)
    Figure 30. United States Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, (2019-2030) & (US$ Million)
    Figure 31. United States Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2023 VS 2030
    Figure 32. United States Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application (%), 2023 VS 2030
    Figure 33. Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, (2019-2030) & (US$ Million)
    Figure 34. Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2023 VS 2030
    Figure 35. Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application (%), 2023 VS 2030
    Figure 36. China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, (2019-2030) & (US$ Million)
    Figure 37. China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2023 VS 2030
    Figure 38. China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application (%), 2023 VS 2030
    Figure 39. Japan Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, (2019-2030) & (US$ Million)
    Figure 40. Japan Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2023 VS 2030
    Figure 41. Japan Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application (%), 2023 VS 2030
    Figure 42. South Korea Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, (2019-2030) & (US$ Million)
    Figure 43. South Korea Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2023 VS 2030
    Figure 44. South Korea Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application (%), 2023 VS 2030
    Figure 45. Southeast Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, (2019-2030) & (US$ Million)
    Figure 46. Southeast Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2023 VS 2030
    Figure 47. Southeast Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application (%), 2023 VS 2030
    Figure 48. India Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value, (2019-2030) & (US$ Million)
    Figure 49. India Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Type (%), 2023 VS 2030
    Figure 50. India Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales Value by Application (%), 2023 VS 2030
    Figure 51. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Industrial Chain
    Figure 52. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Manufacturing Cost Structure
    Figure 53. Channels of Distribution (Direct Sales, and Distribution)
    Figure 54. Bottom-up and Top-down Approaches for This Report
    Figure 55. Data Triangulation
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$3950

This license allows only one user to access the PDF.
Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Novocure

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Colon Cancer Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-31C5944
Mon Apr 15 00:00:00 UTC 2024

Add to Cart

Global CAR T-Cell Immunotherapy Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-10J13802
Mon Apr 15 00:00:00 UTC 2024

Add to Cart

Global Color Detection Sensors Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-6G9623
Mon Apr 15 00:00:00 UTC 2024

Add to Cart

Global Appendix Cancer Treatment Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-2H1312
Mon Apr 15 00:00:00 UTC 2024

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions